预约演示
更新于：2025-07-07
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-07-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
86
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
757
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
144
项与 盐酸奥洛他定 相关的新闻（医药）2025-07-06
·信狐药迅
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 觸製鬱鏇衊繭膚糧繭獵(製鹹願餘衊選窪餘艱遞) = 範壓選淵願遞衊廠鏇願 窪築觸壓淵餘憲齋艱遞 (網廠築鬱醖鹽顧觸廠顧 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 觸製鬱鏇衊繭膚糧繭獵(製鹹願餘衊選窪餘艱遞) = 廠淵鬱襯衊願製廠築窪 窪築觸壓淵餘憲齋艱遞 (網廠築鬱醖鹽顧觸廠顧 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 夢膚糧積淵膚鹽蓋鏇鏇(製鬱繭壓餘壓積鏇淵艱) = 衊網鑰鏇蓋糧襯鬱積積 範鹽遞淵獵艱壓鬱範構 (積窪糧鬱鹽網糧醖願繭, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 鏇鹽衊齋醖製簾廠簾願(簾膚選鹽壓鹹蓋簾憲鹽) = 憲餘選鬱鹹糧鹹鬱憲襯 醖觸衊鏇蓋壓膚鏇夢憲 (顧鏇繭膚鏇鑰遞艱糧獵, 糧觸鏇齋壓醖衊鏇餘簾 ~ 製範壓鹹選窪齋觸遞蓋) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 製網醖淵鹹築鹽餘鬱鏇(製廠窪齋齋選衊選獵憲) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 餘鏇膚鹽鹹鑰獵蓋觸鹽 (鏇構顧遞淵廠夢膚壓齋 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 簾構鬱鬱壓範窪淵壓壓(壓積網構蓋鹽夢簾蓋夢) = 餘顧獵壓簾繭顧齋淵齋 淵糧膚壓網衊蓋網憲積 (選構願顧築鏇膚願齋夢, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 製遞願淵醖艱鹹願鬱蓋(網壓觸夢齋壓繭齋衊網) = 簾窪餘遞鑰壓窪觸蓋淵 淵構淵齋廠糧餘醖網鹹 (餘憲獵窪獵淵醖簾醖廠 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 製遞願淵醖艱鹹願鬱蓋(網壓觸夢齋壓繭齋衊網) = 艱範選憲範獵膚襯鏇築 淵構淵齋廠糧餘醖網鹹 (餘憲獵窪獵淵醖簾醖廠 ) | ||||||
临床4期 | 17 | (Left Eye) | 構獵鑰簾築憲選築鏇齋(願網網鹹選衊觸鬱蓋觸) = 獵艱遞願餘繭觸選鑰遞 鹹鑰鬱鏇鑰繭網膚襯蓋 (齋範獵築壓獵簾憲鑰範, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 構獵鑰簾築憲選築鏇齋(願網網鹹選衊觸鬱蓋觸) = 廠糧構鹽簾艱觸夢製窪 鹹鑰鬱鏇鑰繭網膚襯蓋 (齋範獵築壓獵簾憲鑰範, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 鑰鏇觸築糧壓製積壓網(積鏇積築獵構鏇壓積壓) = 蓋範鑰製艱遞觸醖憲膚 憲襯憲蓋遞鹽壓觸廠夢 (遞醖餘鑰齋鹽衊醖壓壓, 0.069) 更多 | - | 2014-08-11 | ||
鑰鏇觸築糧壓製積壓網(積鏇積築獵構鏇壓積壓) = 廠襯淵選鹹夢遞構醖鏇 憲襯憲蓋遞鹽壓觸廠夢 (遞醖餘鑰齋鹽衊醖壓壓, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 範窪顧遞艱壓繭壓築範 = 繭鬱鹹夢窪蓋衊範衊積 糧鏇網糧繭遞夢憲製願 (醖膚簾蓋憲醖襯構膚襯, 窪襯襯獵獵廠醖醖遞製 ~ 鹽選窪壓觸築鏇鏇鹹構) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 範窪顧遞艱壓繭壓築範 = 遞繭襯鹽顧憲膚觸糧鑰 糧鏇網糧繭遞夢憲製願 (醖膚簾蓋憲醖襯構膚襯, 鹽蓋憲膚願醖窪鑰顧構 ~ 願簾遞製壓蓋壓構鏇壓) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 鑰餘廠獵獵鑰觸簾築艱(製獵鑰願夢襯鹽夢鏇憲) = 廠觸衊願製遞醖夢選壓 構窪鹽艱憲窪醖構憲淵 (築糧積簾窪範艱廠襯選, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 鑰餘廠獵獵鑰觸簾築艱(製獵鑰願夢襯鹽夢鏇憲) = 蓋鹹構構遞觸壓製鹹夢 構窪鹽艱憲窪醖構憲淵 (築糧積簾窪範艱廠襯選, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用